← SynDRA
SB-431542
SynDRA canonical compound SYN0000026 — structure-anchored drug synonym record
| Clinical phase | Preclinical |
|---|
| Primary target(s) | TGFBR1 |
|---|
| Mechanism of action | TGF beta receptor inhibitor |
|---|
| Indication | brain tumors |
|---|
| Disease area | Oncology |
|---|
All known targets
- TGFBR1
- ACVR1C
- A1BG
- ACVR1B
Mechanisms of action (all sources)
- TGF beta receptor inhibitor
- ACVR1C INHIBITOR
- TGFBR1 INHIBITOR
- activin receptor inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- AAK1
- PAK2
- PDK1
- PDGFRB
- PDGFRA
- PASK
- PAK6
- PAK5
- PAK4
- PAK3
- PAK1
- PRKCB
- NUAK2
- NUAK1
- NTRK3
- NTRK2
- NTRK1
- NLK
- NEK9
- NEK7
- PDPK1
- PHKG1
- PHKG2
- PI4KB
- PRKACB
- PRKACA
- PRKAA2
- PRKAA1
- PLK4
- PLK3
- PLK1
- PKN2
- PKN1
- PKMYT1
- PIP5K1A
- PIP4K2B
- PIM3
- PIM2
- PIM1
- PIK3CD
Cross-references
Synonyms
- SB 431542
- 4-(4-(benzo[d][1,3]dioxol-5-yl)-5-(pyridin-2-yl)-1H-imidazol-2-yl)benzamide
- SB431542
- UNII-E1557V1V0N
- CHEMBL440084
- E1557V1V0N
- 4-[4-(1,3-BENZODIOXOL-5-YL)-5-(2-PYRIDINYL)-1H-IMIDAZOL-2-YL]BENZAMIDE
- 4-(4-(1,3-Benzodioxole-5-yl)-5-(2-pyridyl)-1H-imidazole-2-yl)benzamide
- SB 431542 hydrate
- C22H16N4O3
- 4-[4-(3,4-Methylenedioxyphenyl)-5-(2-pyridyl)-1H-imidazol-2-yl]benzamide
- 4-(4-Benzo[1,3]dioxol-5-yl-5-pyridin-2-yl-1H-imidazol-2-yl)-benzamide
- J1.722.247C
- RefChem:1069917
- DTXCID5022693
- MFCD05865244
- SB-431542 (GMP)
- SB-431542-A
- SR-01000597591
- 3tzm
- Bio2_000852
- MFCD11045982
- Kinome_3428
- BSPBio_001064
- KBioGR_000404
- KBioSS_000404
- MLS006010130
- SCHEMBL155156
- SCHEMBL310028
- SB-431542 (Standard)
- GTPL8216
- orb1307603
- SCHEMBL29353092
- SCHEMBL29359059
- SCHEMBL29381798
- SCHEMBL30033986
- BCBcMAP01_000166
- CHEBI:91108
- cid_4521392
Look up SB-431542 in the interactive SynDRA portal →